C.R. Bard to license hernia product, technology from Genzyme Corp.
C.R. Bard Inc. Monday said it has entered into a license agreement with Genzyme Corp. to manufacture and market the Sepramesh IP hernia repair product line and to incorporate the related Sepra coating technology into the development of future hernia repair applications. Bard’s Davol subsidiary will begin marketing the line immediately, the companies said.
Details of the agreement were not disclosed.
Shares of Murray Hill, N.J.-based C.R. Bard closed Friday at $83.50, while shares of Cambridge, Mass.-based Genzyme closed at $74.88.
VIA: Forbes.com
Written by admin on December 20th, 2007 with
no comments.
Read more articles on Hernias.
- [+] Digg: Feature this article
- [+] Del.icio.us: Bookmark this article
- [+] Furl: Bookmark this article